Prognostic factors for patients with small cell lung carcinoma

作者：Marianne Paesmans, Jean‐Paul Sculier, J. Lecomte, Jacques Thiriaux, P Libert, ROGER SERGYSELS, Gérard Bureau, G Dabouis, Oswald Van Cutsem, P. Mommen, Vincent Ninane, Jean A. Klastersky, for the European Lung Cancer Working Party · 发表于：Cancer · 年份：2000 · DOI：10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6 · 被引用次数：222 · 研究领域：Lung Cancer Research Studies、Inflammatory Biomarkers in Disease Prognosis、Immune cells in cancer

BACKGROUND: The purposes of this study were to identify prognostic factors for response to chemotherapy, overall survival, and long term survival of patients with small cell lung carcinoma and to construct a classification of patients on the basis of their expected overall survival. METHODS: In the 763 patients registered in 4 consecutive clinical trials conducted by the European Lung Cancer Working Party from 1982 to 1993, the impact of 21 pretreatment variables assessable in a routine practice was analyzed for the various outcomes with a minimum follow-up of 5 years. RESULTS: The key prognostic role of disease extent was confirmed for all the outcomes. Additional independent prognostic factors for response to chemotherapy were gender, neutrophil count, and hemoglobin level; for overall survival, these factors were Karnofsky performance status, gender, and neutrophil count. Recursive partitioning and amalgamation algorithms (RECPAM) analysis classified patients into 4 groups, taking into consideration disease extent, Karnofsky performance status, age, gender, and neutrophil count. Median survival times for the 4 groups were 60, 47, 36, and 28 weeks, respectively. For long term survival, defined as a minimum survival of 2 years (9% of the patients), Karnofsky performance status was the only independent predictive factor, along with the achievement of a complete response (if this was taken into consideration). Small cell lung carcinoma remained the main cause of death among th...